论文部分内容阅读
目的评价多巴胺受体激动剂 -吡贝地尔 (Peribedil)缓释片与复方左旋多巴联合疗法对帕金森病 (PD)的功效和可接受性。方法在单独服用复方左旋多巴的基础上，合用吡贝地尔治疗 PD。合并用药前后分别采用韦氏量表 (Weste Scale Modifired)进行评分，观察 2～ 8个月。结果 33例 PD患者中有 29例症状改善，总值评分由 (16.9± 2.1)降为 (12.8± 2.7)分 (P< 0.05)，主要症状中震颤改善反应最佳。结论吡贝地尔缓释片与复方左旋多巴联合治疗 PD，在不增加甚至减少原复方左旋多巴剂量的基础上， PD症状的改善优于单独复方左旋多巴疗法。
Objective To evaluate the efficacy and acceptability of dopamine receptor agonist - combination of Peribedil sustained-release tablets and compound levodopa for Parkinson’s disease (PD). Methods Based on taking compound levodopa alone, we treated with piribedil in the treatment of PD. Before and after the combination therapy were used Weste Scale Modifired score, observed 2 to 8 months. Results Twenty-nine of the 33 patients with PD improved their symptoms. The total score decreased from (16.9 ± 2.1) to (12.8 ± 2.7) points (P <0.05). The main symptoms were the best response to tremor. Conclusions The combination of piribedil and compound levodopa in the treatment of PD is superior to the single compound levodopa therapy without increasing or even decreasing the original compound levodopa dosage.